Implantable cardioverter-defibrillator therapy in clinical practice

Area of Science:

• Cardiology
• Medical Devices
• Heart Failure Management

Background:

• Pharmacologic treatments have improved heart failure survival and quality of life.
• Heart failure can progress despite optimal medical therapy, leaving patients at risk for sudden cardiac death.
• Sudden cardiac death incidence in the U.S. is significant, estimated between 184,000 to over 400,000 cases annually.

Purpose of the Study:

• To review the current status of implantable cardioverter-defibrillator (ICD) therapy in heart failure patients.
• To summarize evidence from randomized clinical trials and practice guidelines regarding ICD use in heart failure.
• To discuss the evolving role of device-based therapy in managing heart failure.

Main Methods:

• Review of randomized clinical trial results.
• Analysis of published practice guidelines.
• Synthesis of current evidence on ICD therapy for heart failure.

Main Results:

• Device-based therapies, particularly ICDs, have advanced significantly over the past decade.
• ICD therapy plays an evolving role in the routine management of heart failure patients.
• Evidence from clinical trials and guidelines supports the use of ICDs in specific heart failure populations.

Conclusions:

• Implantable cardioverter-defibrillators are a crucial component of modern heart failure management.
• Ongoing research and guideline updates continue to refine the indications for ICD therapy.
• Device therapy offers a vital strategy to mitigate the risk of sudden cardiac death in heart failure.